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Update on Intraperitoneal Chemotherapy for the Treatment
of Epithelial Ovarian Cancer
Charlie Gourley, BSC, MBChB, PhD, FRCP, Joan L. Walker, MD, and Helen J. Mackay, BSc, MBCh, MD,MRCP
OVERVIEW
Surgical treatment and chemotherapy administration in women with epithelial ovarian cancer is more controversial today
than at any point in the last 3 decades. The use of chemotherapy administered intraperitoneally has been particularly
contentious. Three large randomized phase III studies, multiplemeta-analyses, and now real-world data have demonstrated
substantial outcome benefit for the use of chemotherapy administered intraperitoneally versus intravenously for first-line
postoperative treatment of optimally debulked advanced ovarian cancer. Unfortunately, for each of these randomized
studies, therewas scope to either criticize the design or otherwise refute adoption of this route of administration. As a result,
the uptake has been variable in North America, although in Europe it has been practically nonexistent. Reasons for this
include unquestionable additional toxicity, more inconvenience, and extra cost. However, 10-year follow up of these studies
demonstrates unprecedented survival in the intraperitoneal arm (median survival 110 months in patients with completely
debulked stage III), raising the possibility that by combining maximal debulking surgery with postoperative intraperitoneal
chemotherapy it may be possible to bring about a step change in the outcomes for these patients. In this review, we discuss
the rationale for administering chemotherapy intraperitoneally, the merits of the main randomized clinical trials, the
evidence regarding optimal regimes, issues of toxicity, port considerations, and reasons for lack of universal adoption. We
also explore potential clinical and biologic factors that may be useful for patient selection in the future.
Wehave witnessed improvements in epithelial ovariancancer survival over the last 3 decadeswithout seeing
significant improvements in disease-specific mortality rates
(Fig. 1). Epithelial ovarian cancer remains the leading cause
of death from gynecologicmalignancy in North America with
the majority of women presenting with stage III or IV dis-
ease.1,2 Advances in genetic testing, counseling, and pre-
vention with risk-reducing salpingo-oophorectomy (and
salpingectomy) have the potential to produce further
modest decreases in ovarian cancer mortality in the future.3
However, we currently do not have a reliable population
screening test for epithelial ovarian cancer, and, given the
often nonspecific symptoms with which epithelial ovarian
cancer presents, it is likely the majority of patients will
continue to present with late-stage disease. Therefore,
optimizing treatment is critical if we are to improve outcome.
Retrospective analyses suggest that overall survival (OS) is
associated with younger age, good performance status,
lower stage of disease, and lower comorbidity scores.4,5
Although histologic subtype and tumor grade previously
were regarded as simply prognostic, it has now become clear
that they represent pathologic markers of what are essen-
tially discrete disease entities. These differ in terms of their
tissue of origin, stage of presentation, driver molecular
mutations, sensitivity to chemotherapy, and prognosis
(Fig. 2). Ultimately, it is very likely that these histologic
subtypes will require different treatment strategies.6
In clinical practice, only a few risk factors remain that can
be modified based on the decisions of patients and their
physicians. The surgical decision making and chemotherapy
administration choices, particularly for women with stage III
or IV epithelial ovarian cancer, can potentially affect survival.
Informed selection of the best treatment (including clinical
trial options) for any individual patient is most likely to be
achieved with enthusiastically committed multidisciplinary
teams working in high-volume institutions.7,8 Discussions
around chemotherapy administered intraperitoneally for
individual patients require this type of environment to allow
the patient to make an informed choice about care.
This article summarizes the history and role of chemo-
therapy administered intraperitoneally in epithelial ovarian
cancer, focuses on the practical choices that patients and
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clinicians face (with an emphasis on emerging data), and
stresses the importance of building skilled multidisciplinary
teams for treating women undergoing intraperitoneal
treatment. Finally, we explore how emerging data on epi-
thelial ovarian cancer biology may be able to guide the
future of intraperitoneal therapy in this disease.
RATIONALE FOR INTRAPERITONEAL
CHEMOTHERAPY
The peritoneal cavity is the principle site of spread and
recurrence in women with epithelial ovarian cancer. Ad-
ministration of chemotherapy intraperitoneally is ameans of
increasing the dose intensity delivered to the tumor and
minimizes systemic toxicity, therefore, it is an attractive
therapeutic approach.9 Advantages of intraperitoneal ad-
ministration include high intraperitoneal concentration of
the drug, as well as a longer half-life of the drug in the
peritoneal cavity, compared with that observed with ad-
ministration intravenously alone. For cisplatin, historically,
the most extensively studied agent administered by the
intraperitoneal route in epithelial ovarian cancer translates
into a 10- to 20-fold greater exposure over that which is
achievable with the intravenously administrated route.10-12
Furthermore, preclinical studies suggested that cisplatin is
capable of penetrating small volume tumors (1–3 mm).
Hence, the hypothesis arose that themaximum benefit from
administration of the drug intraperitoneally was likely to be
demonstrated in patients with microscopic or low-volume
macroscopic disease.13 However, our understanding of why
the intraperitoneal chemotherapy route is more effective
may be oversimplified, and it has been challenged. Mea-
surement of drug in peritoneal fluid probably does not
represent actual tumor drug penetration in patients.14 There
may be added barriers in tumor implants, notably disordered
capillary architecture, fibrosis, and adhesions. Furthermore,
dose intensification of platinum administered intravenously
has failed to show a benefit in multiple randomized stud-
ies.15,16 However, these dose intensification studies did not
select neither patients with high-grade serous ovarian
cancer nor the subgroups with disease that we know to be
most sensitive to platinum (those exhibiting homologous
recombination deficiency, discussed below). As such, the
impact in the dose-dense arms of these studies (which were
twice the density of the control arm at most) in any patients
with disease sensitive to this approach would be diluted out
by themajority of patientswhose tumor biologywouldmake
them unlikely to benefit from this approach. Although the
intraperitoneal studies were similarly unselected for
immunohistologic or molecular subtype, the local dose in-
tensification in the intraperitoneal arm is potentially an
order of magnitude higher than in the intravenously ad-
ministrated arm. Under these circumstances, it may be
possible that the signal would be evident even without
preselection on the basis of histology or biology.
Other factors such as drug recirculation following peri-
toneal absorptionmay play a role in efficacy. Despite the fact
that chemotherapy administered intraperitoneally has been
studied for decades, we are still not fully aware of the key
biologic factors that determine its success.15,16 Moving
forward, a greater understanding of how tumor biology and
the immune and micro-environments are affected by
treatment administered intraperitoneally may help us un-
derstand how this treatment can best be deployed and
combined with the newer generation of targeted agents.
INTRAPERITONEAL CHEMOTHERAPY TRIALS IN
WOMEN WITH EPITHELIAL OVARIAN CANCER
Intraperitoneal chemotherapy is not a recent concept in the
treatment of epithelial ovarian cancer; it was originally used
FIGURE 1. Increase in Overall Survival Over Time for
Women Diagnosed With Ovarian Cancer
KEY POINTS
• Patientswith epithelial ovarian cancer should be treated
by high-volume multidisciplinary teams.
• Randomized phase III trial, meta-analysis, and real-
world data support the benefit of chemotherapy
administered intraperitoneally in the treatment of
select groups of women with epithelial ovarian cancer
following up-front optimal cytoreductive surgery.
• The optimal intraperitoneal/intravenous chemotherapy
regimen has yet to be defined, and emerging data from
the randomized studies GOG 252, OV21/PETROC, and
JGOG iPocc will help clarify whether cisplatin
administered intraperitoneally can be replaced by
carboplatin administered intraperitoneally.
• Discussion of chemotherapy administered
intraperitoneally to treat women diagnosed with
ovarian cancer is essential.
• Understanding the biology underlying the success of
chemotherapy administered intraperitoneally is a
priority; initial data suggest exploration of tumors
deficient in DNA repair are of particular interest.
144 2016 ASCO EDUCATIONAL BOOK | asco.org/edbook
GOURLEY, WALKER, AND MACKAY
in the 1950s to control ascites. Interest in chemotherapy
administered intraperitoneally as a strategy for reducing
the risk of disease recurrence and prolonging survival
emerged approximately 30 years ago. This resulted in a
number of randomized phase III studies that demonstrated
an improvement in survival for the combination of delivery
of chemotherapy intraperitoneally and intravenously over
chemotherapy administrated intravenously alone for
select patients following primary cytoreductive surgery
(Table 1).17-23 GOG 172, a randomized phase III study of
cisplatin administered intraperitoneally combined with
both delivery of paclitaxel intraperitoneally and intravenously,
published in 2006, demonstrated a 16-month improvement
in median OS over intravenous administration of the same
drugs alone.18 This prompted the National Cancer Institute
(NCI) to issue a rare clinical announcement regarding the
clinical utility of cisplatin-based chemotherapy adminis-
tered intraperitoneally in the treatment of patients with
small volume (, 1 cm), advanced-stage (stage III) epithelial
ovarian cancer following an attempt at maximal cytore-
ductive surgery. On average, intraperitoneal/intravenous
chemotherapy was associated with a 21.6% decrease in
risk of death (hazard ratio (HR) 0.78; 95% CI, 0.69–0.89,
the original clinical announcement can be viewed at ctep.
cancer.gov).
An update published in 2015 with a median follow-up
of 10.7 years showed that women who underwent
intraperitoneal/intravenous chemotherapy in GOG 172
continued to derive benefit with a median survival of
61.8 months (95% CI, 55.5–69.5 months) compared with
51.4 months (95% CI, 46–58.2 months) for chemotherapy
administered intravenously alone.24 The recent Cochrane
Review, restricted to newly diagnosed patients receiving
treatment after primary cytoreductive surgery, accepted
data from eight randomized studies on 2,026 women and
TABLE 1. Summary of Randomized Clinical Trials of Intraperitoneal Chemotherapy for Up-Front Primary
Cytoreductive Surgery
Study/Reference Control Regimen Experimental Regimen Eligible Patients
No. of
Patients
Kirmani et al20 Cisplatin 100 mg/m2 IV cyclophosphamide
600 mg/m2
Cisplatin 200 mg/m2 IP; etoposide 350 mg/m2 IP Stage IIC-IV 62
Every 3 weeks x 6 Every 4 weeks x 6
SWOG 8501/
GOG 10417
Cisplatin 100 mg/m2 IV; cyclophosphamide
600 mg/m2 IV
Cisplatin 100 mg/m2 IP; cyclophosphamide
600 mg/m2 IV
Stage III,
# 2 cm residual
546
Every 3 weeks x 6 Every 3 weeks x 6
Polyzos et al22 Carboplatin 350 mg/m2 IV; cyclophosphamide
600 mg/m2 IV
Carboplatin 350 mg/m2 IP; cyclophosphamide
600 mg/ m2 IV
Stage III 90
Every 3 weeks x 6 Every 3 weeks x 6
GONO19 Cisplatin 50 mg/m2 IV; cyclophosphamide
600 mg/m2 IV; epidoxorubicin 60 mg/m2 IV
Cisplatin 50 mg/m2 IP; cyclophosphamide
600 mg/ m2 IV; epidoxorubicin 60 mg/m2 IV
Stage II-IV,
, 2 cm residual
113
Every 4 weeks x 6 Every 4 weeks x 6
GOG 114/
SWOG 922721
Cisplatin 75 mg/m2 IV; paclitaxel
135 mg/m2 (24-hr) IV
Carboplatin (AUC 9) IV every 28 days x 2;
cisplatin 100 mg/m2 IP; paclitaxel
135 mg/m2 (24-hr) IV
Stage III,
# 1 cm residual
462
Every 3 weeks x 6 Every 3 weeks x 6
Yen et al23 Cisplatin 50 mg/m2 IV; cyclophosphamide
50 mg/m2 IV; epidoroxorubin/
doxorubicin 50 mg/m2 IV
Cisplatin 100 mg/m2 IP; cyclophosphamide
500 mg/m2 IV; epidoxorubicin/
doxorubicin 50 mg/m2 IV
Stage III,
# 1 cm residual
118
Every 3 weeks x 6 Every 3 weeks x 6
GOG 17218 Cisplatin 75 mg/m2 IV; paclitaxel
135 mg/m2 (24-hr) IV
Paclitaxel 135 mg/m2 (24-hr) IV; cisplatin
100 mg/m2 IP; paclitaxel 60 mg/m2 IP on day 8
Stage III,
# 1 cm residual
415
Every 3 weeks x 6 Every 3 weeks x 6
Abbreviations: IP, intraperitoneally; IV, intravenously.
FIGURE 2. Schema for GOG 252
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concluded that women experienced increased survival if
they received intraperitoneal/intravenous chemotherapy
(HR 0.81; 95% CI, 0.70–0.9) and that intraperitoneal/
intravenous chemotherapy also prolonged the disease-
free interval (five studies, 1,311 women; HR 0.78; 95% CI,
0.7–0.86),25 thus potentially affecting quality of life going
forward.
Wright et al recently reported data on the real-world
uptake of intraperitoneal/intravenous chemotherapy in a
prospective cohort of 823 women with stage III optimally
cytoreduced epithelial ovarian cancer treated in six National
Comprehensive Cancer Network (NCCN) institutions.8 De-
spite the trial-based evidence and although adoption of
intraperitoneal/intravenous chemotherapy increased be-
tween 2007 and 2008, it plateaued with fewer than 50% of
eligible patients receiving intraperitoneal/intravenous
treatment. They also observed marked variation in up-
take between institutions from 4% to 67%, suggesting
underutilization of this effective treatment approach in
this subgroup of women.
WHY HAS INTRAPERITONEAL/INTRAVENOUS
CHEMOTHERAPY NOT BEEN UNIVERSALLY
ADOPTED?
Despite a proven survival benefit, clearly intraperitoneal/
intravenous chemotherapy has not been universally adop-
ted for the treatment of epithelial ovarian cancer. The
reasons behind this are numerous. The publication of each
positive intraperitoneal/intravenous randomized study has
been met with considerable debate over the interpretation
of the trial data.26 Arguments around the validity of the
conclusions drawn from GOG 172 have included statistical
analysis queries (intention-to-treat analysis, number of
patients lost to follow-up), and questions over second-line
treatment and scheduling effects.26 The most relevant
criticism of the pivotal intraperitoneal studies is the in-
equality of dose intensity between the treatment arms in
both GOG11421 and GOG17218 (Table 1). Given the fact that
paclitaxel administered intravenously weekly has been
shown to be superior to paclitaxel administered in-
travenously tri-weekly in one large randomized phase III
study,27 it could be argued that the administration of
an additional dose of paclitaxel on day 8 in the Armstrong
study was solely responsible for the benefit demonstrated.
However, a second randomized phase III study of weekly
versus triweekly paclitaxel administered intravenously did
not show superiority.28 In addition, the Alberts’ (GOG104)
study was a clean comparison of the same doses of cisplatin
administered intravenously or intraperitoneally, which
demonstrated substantial progression-free and OS advan-
tages,17 but it was overlooked in many areas of the world
because paclitaxel came to prominence and the comparator
arm in GOG104 was regarded as outdated. It does, however,
serve as a useful proof of principle regarding the advantages
that can be attributed purely to the route of administration.
In addition, when the two studies with unequal dose
intensities between the arms (GOG 114 and GOG 172)
were excluded from the analysis of a Cochrane systematic
review in 2011, the survival benefit remained in favor of
the intraperitoneal route of administration.25 In the real-
world analysis by Wright et al, 43% of patients received
modified intraperitoneal/intravenous regimens over time
(i.e., regimens differing from trial-specified protocols). De-
spite these modifications, women receiving intraperitoneal/
intravenous chemotherapy continued to derive benefit over
those who only received treatment intravenously (3-year OS
81% vs. 71%; HR 0.68; 95% CI, 0.47–0.99).8
Undoubtedly, delivery of intraperitoneal/intravenous
chemotherapy requires increased resources in terms of
both space and time to deliver compared with therapy
administrated intravenously. Because of placement of
catheters and regional delivery of drug, intraperitoneal/
intravenous chemotherapy is potentially associated with
greater toxicity, including catheter-related complications,
gastrointestinal toxicity, pain, and infection. These have
been reported across trials and supported in meta-ana-
lyses.25,29 However, real-world reports suggest many of
these potential issues can be overcome with time and de-
velopment of expertise.30,31 Furthermore, randomized data
and the NCI alert support the use of cisplatin administered
intraperitoneally.17-21,23 Cisplatin is known to be more toxic
than the standard of care carboplatin, which is administered
intravenously for epithelial ovarian cancer.32 To date, we do
not have randomized trial data to determine whether car-
boplatin administered intraperitoneally is equivalent to
cisplatin administered intraperitoneally in terms of its im-
pact on survival. However, preclinical and some clinical data
suggest that it might be equivalent in efficacy and less
toxic than cisplatin administered intraperitoneally.33 Results
fromGOG252 (NCT00951496) andOV21/PETROC (NCT00993655)
are awaited. These trials include direct comparison of
regimens, including cisplatin and carboplatin administered
intraperitoneally.
As yet, we have not arrived at the optimal intraperitoneal/
intravenous chemotherapy regimen,which balances efficacy
with toxicity and quality of life. Finally, effective and safe
delivery of intraperitoneal/intravenous chemotherapy re-
quires themultidisciplinary expertise of a skilled team,which
simply may not be available in smaller-volume centers.
Therefore, consideration for referral and management in
high-volume centers is appropriate. Even with all the con-
cerns that exist, it is clear that women who are appropriate
for intraperitoneal/intravenous chemotherapy should be at
least offered this as an option, and clinicians should be
considering how best to make it available to them.31
SURGICAL CONSIDERATIONS FOR
INTRAPERITONEAL CHEMOTHERAPY
The goal of ovarian cancer surgery whenever it is performed
is no gross residual disease or R0, as defined by Chi and
Bristow.7,34 This has been shown to result in improved
progression-free survival (PFS) and OS. Intraoperative
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treatment decisions that have been demonstrated to in-
fluence patient survival and maximize surgical effort must
include a willingness to perform diaphragm resection,
splenectomy, bowel resections, and thorough peritoneal
and retroperitoneal resections of tumor. This requires ex-
perience and potentially a team of surgeons.35 Although an
R0 resection improves OS, it remains somewhat unclear
whether microscopic versus visible disease has an impact on
intraperitoneal chemotherapy effectiveness, as the allow-
able residual volume at the end of surgery differed in
the randomized trials (, 2 or , 1 cm). Many have made
the assumption that patients with microscopic disease
would derive the greatest benefit from intraperitoneal/
intravenous chemotherapy. However, in a subgroup analysis
of the GOG172 patient population, the 64% of women in
GOG172 who had macroscopic (gross) residual disease less
than or equal to 1 cm (which was the upper limit allowed by
study eligibility) had a significant improvement in OS (HR
0.75; 95% CI, 0.62–0.92).24 Further exploration of the effect
on larger-volume residual disease should emerge fromGOG-
0252 and the Japanese iPocc trial (NCT01506856), both of
which enrolled a proportion of patients with larger-volume
residual disease.
Landrum looked into the effects of lymphadenectomy and
nodal metastasis on the benefit of administering chemo-
therapy intraperitoneally using data from both GOG 114 and
GOG 172. In these studies, despite undergoing cytoreductive
surgery to less than 1 cm, only 59% of women had lymph
nodes sampled or excised. Of the 254womenwho had lymph
node evaluation, intraperitoneal benefit in terms of PFS and
OS was independent of nodal status. This suggests that
chemotherapy administered intraperitoneally may be equally
effective for patients with both intraperitoneal and retro-
peritoneal disease. Interestingly, the patients without lym-
phadenectomy did worse than patients with metastatic
tumor removed from their lymph nodes, although the de-
cision not to perform the lymphadenectomy may have been
secondary to some poor prognostic factor perceived by the
surgeon. An important long-term quality of life finding by
Landrumwas adecrease in recurrence in the abdominal cavity
after intraperitoneal chemotherapy. Thus intraperitoneal/
intravenous treatment may spare patients from suffering
from ascites and an inability to eat when they recur.4
A key and controversial area around surgical decision
making in epithelial ovarian cancer is the choice of neo-
adjuvant chemotherapy followed by a definitive cytore-
ductive surgical attempt versus primary cytoreductive
surgery. Initially, neoadjuvant chemotherapy was consid-
ered only for those women who were medically unfit for
aggressive surgery or for women with a high tumor burden
(especially those with stage IV disease).36,37 In recent years,
the use of neoadjuvant chemotherapy has gained in pop-
ularity. This followed the publication of two studies: the
European Organization for Research and Treatment of
Cancer Gynecologic Cancer Group (EORTCGCG) 5597138 and
the CHORUS study,39 which demonstrated equivalence in
outcome with some reduction in morbidity for patients
receiving neoadjuvant treatment. Neoadjuvant chemo-
therapy is usually platinum-based and administered in-
travenously; there is no role for intraperitoneal/intravenous
therapy in the preoperative patient. A recent study by Rosen
et al40 showed that the long-term survival for patients
undergoing primary cytoreduction was far superior to those
receiving neoadjuvant chemotherapy and delayed primary
surgery (9% vs. 41%, p, .0001). Although selection biasmay
account for some of this difference, the percentage of long-
term survivors is strikingly low in neoadjuvant chemother-
apy studies.41 Patients undergoing optimal cytoreductive
surgery following administration of neoadjuvant chemo-
therapy were not included in the previous intraperitoneal/
intravenous randomized trials. Theoretically, they may
derive a similar level of benefit to women undergoing
up-front cytoreductive surgery from intraperitoneal/
intravenous chemotherapy delivery. The combination of
intraperitoneal/intravenous chemotherapy following neo-
adjuvant chemotherapy and optimal cytoreductive surgery
is being studied in the Gynecologic Cancer Intergroup study
OV21/PETROC. Women who had initial (clinical/imaging)
stage IIB-IV (intravenously based on the presence of pleu-
ral effusion alone) epithelial ovarian cancer and who had
received three or four cycles of platinum-based neoadjuvant
chemotherapy before definitive optimal cytoreductive
surgery (# 1 cm residual disease) were eligible for this trial.
Women were enrolled either intra- or postoperatively. This
study has now closed and the primary analysis is expected
shortly.
INTRAPERITONEAL PORT PLACEMENT
Essential to the delivery of chemotherapy administered in-
traperitoneally is the placement of an intraperitoneal port.
Consideration of port placement should occur at the time of
surgery when the port can be placed under direct visuali-
zation by the surgeon. This is the most time-efficient ap-
proach and prevents delays in the initiation of chemotherapy
postoperatively. Patients should be treated as soon as they
have resumed a normal diet and bowel function and are
ambulatory at home, which should occur within 21 days
of the primary surgery. Patients electing to receive in-
traperitoneal chemotherapy who do not already have
peritoneal catheters can have devices implanted by inter-
ventional radiologists or surgeons familiar with laparoscopic
techniques using the right upper quadrant entry techniques.
Minilaparotomy in the right lower quadrant is also generally
successful if resection of the terminal ileumor right colon did
not occur. Careful review of the cytoreduction operative
report can improve outcomes with intraperitoneal port
placement to avoid complications.42,43
The preferred location for port placement is the right
lower costal grill on themidclavicular line, below the location
where the breast or the bra may be uncomfortable in
a standing position. This site allows for posterior rigid
support that facilitates access. Ports also are installed over
the left side or right lower quadrant for convenience.
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Failures of intraperitoneal catheters can be corrected in-
frequently. Infected catheters should be removed and not
replaced. Blocked catheters can be replaced if the patient
has free intraperitoneal space remaining between bowel
loops and has not had peritonitis as a complication of having
undergone surgery or having received chemotherapy. Ac-
cess problems attributable to a rotated port can be easily
corrected. Most patients, however, resume their chemo-
therapy with treatment administered intravenously alone
when catheter complications occur.
INTRAPERITONEAL CHEMOTHERAPY: WHICH
REGIMEN?
The 2013 update of the NCCN Guidelines suggested an in-
traperitoneal regimenbasedon the experimental armofGOG
172: cisplatin administered intraperitoneally 75 to100mg/m2
anda 3-hour infusion of paclitaxel intravenously onday1with
60mg/mg2 delivered intraperitoneally on day 8. The reduced
dose of cisplatin administered intraperitoneally (75 mg/m2)
was includedbecause of concerns over the toxicity of 100mg/
m2 with patients who did not complete the planned six cycles
of intraperitoneal/intravenous therapy postsurgery. This
dosing is also reflected in the experimental arms of both GOG
252 and OV21/PETROC.44
Given the toxicity associated with cisplatin and the
emerging nonrandomized data on carboplatin administered
intraperitoneally, some centers have adopted intraperitoneal
carboplatin-based regimens.45,46 Randomized data to better
inform the selection of an intraperitoneal/intravenous regi-
men will be available soon from GOG 252 and OV21/PETROC.
Given that GOG 172 demonstrated an OS benefit in an
intention-to-treat analysis when the median number of
cycles deliveredwas three (although the studies to date have
looked at six cycles of chemotherapy), a question remains
as to whether six is the optimal number of intraperitoneal
treatments.18
When discussing chemotherapy options for patients
whose disease is optimally cytoreduced, clinicians face the
challenge of discussing three basic choices: (1) carboplatin
and paclitaxel administered intravenously every 3 weeks
(GOG 158, GOG 182), (2) carboplatin administered in-
travenously every 3 weeks with paclitaxel administered
intravenously weekly (JGOG-3016, GOG 262), or (3) an
intraperitoneal/intravenous regimen.32,42,47,48 The subset of
women with stage III optimally cytoreduced disease in ICON
7 did not derive benefit from the addition of bevacizumab to
carboplatin and paclitaxel administered intravenously every
3 weeks.49 Data from OV21/PETROC, GOG 252, and JGOG
iPocc (NCT01506856) studies are eagerly awaited because
they will provide information on the comparison of a dose-
dense intravenous regimen with intraperitoneal/intravenous
chemotherapy. This will address the question of dose density
that remains from theGOG172data. The role of bevacizumab
in combination with intraperitoneal/intravenous chemo-
therapy is being explored in GOG252. The tolerability of the
regimen was established in a previous phase II trial, although
three bowel obstructions (7%) were observed.50 Further
safety data on the combination of bevacizumab and
intraperitoneal/intravenous therapy will be available from
GOG 252. GOG 262 is a study that compared carboplatin/
paclitaxel administered intravenously every 3 weeks with
carboplatin administered intravenously on day 1 with
weekly dosing of paclitaxel intravenously. Bevacizumab
was allowed as an (nonrandomized) option in both arms of
the trial. This study demonstrated that dose-dense pacli-
taxel improve PFS over the dosing of paclitaxel every
3 weeks, but this was only true in women not receiving
bevacizumab. The addition of bevacizumab appeared to
eliminate the beneficial effects of dose-dense pacli-
taxel.47 In GOG 252, bevacizumab is included on cycles
2–22, and the study was designed with the assumption
that there would be no interaction between the various
chemotherapy arms and bevacizumab, which would hide
the effects of the individual chemotherapy regimens. The
surprising results of GOG 262 raise concern that the ad-
dition of bevacizumab to all patients on GOG 252 may
have obscured the effects of the individual chemotherapy
regimens alone. Insufficient data exist at this time to rec-
ommend bevacizumab in combination with intraperitoneal/
intravenous chemotherapy as a standard-of-care option.
Results for GOG 252 are expected to be reported at the
Society of Gynecologic Oncology meeting in March 2016.
Ultimately, the factors that patients and families should be
empowered to consider when making decisions about ad-
juvant treatment will include convenience, potential toxic-
ities, and quality of life in addition to the data on efficacy.
PATIENT SELECTION FOR INTRAPERITONEAL
CHEMOTHERAPY
The last consideration is whether there are individual
patient findings that should be factored into decisions
regarding whether chemotherapy should be administered
intraperitoneally/intravenously or just intravenously to pa-
tients. It is now clear that at the immunohistochemic level,
epithelial ovarian cancer consists of at least five different
diseases.51-53 Although previous randomized studies of
intraperitoneal/intravenous chemotherapy versus in-
travenous chemotherapy did not select or stratify on the basis
of histologic subtype, it is now apparent that subtypes such as
low-grade serous, low-grade mucinous, and clear cell are less
sensitive to chemotherapy than high-grade serous or high-
grade endometrioid ovarian cancer. The low likelihood of a
considerable chemotherapy dose-response relationship in
these less-sensitive subtypes makes it difficult to justify
subjecting these patients to the additional toxicity of in-
traperitoneal chemotherapy. Rather, the main subgroup of
patients who should be considered for intraperitoneal ad-
ministration of chemotherapy are those with high-grade
serous ovarian cancer (patients with high-grade endome-
trioid cancer are an under-researched subgroup), but what
little evidence there is suggests they could be considered
similar to high-grade serous from a biologic perspective).
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Currently, given the strong evidence of benefit from GOG
11421 and GOG17218 studies, there is insufficient evidence to
support any further patient selection based on biologic
subtype in patients with optimally cytoreduced disease who
have good performance status. However, the finding that
patients from the GOG 172 study with low-tumor BRCA1
expression (as assessed by immunohistochemistry) appeared
to benefit more from intraperitoneal/intravenous che-
motherapy than intravenous chemotherapy (median sur-
vival 84 compared with 48 months, p = .0002) than those
with normal BRCA1 expression (median survival 58 months
for intraperitoneal chemotherapy compared with 50 months
for intravenous chemotherapy) suggests that there are
molecular subgroups that may benefit more from the in-
traperitoneal route of delivery.54 The main molecular
characteristics underlying high-grade serous ovarian can-
cer have recently been uncovered (Fig. 3).51,55 Given the
strong preclinical and clinical data supporting a high level of
platinum sensitivity in BRCA1- and BRCA2-deficient ovarian
cancer cells, it is not surprising that patients with low
BRCA1 protein expression may derive particular benefit
from administration of chemotherapy intraperitoneally.
The question is whether this benefit applies only to tumors
that carry germline or somatic BRCA1mutations, or whether
those patients with epigenetic BRCA1 inactivation, BRCA2
mutations, PTEN loss, EMSY amplification, or mutations in
other homologous recombination deficiency genes also de-
rive benefit. Although BRCA1 immunohistochemistry analysis
is notoriously inaccurate, the technology now exists to per-
form this other sequencing and copynumber characterization
on archival formalin-fixed, paraffin-embedded material. This
retrospective analysis should be performed as a matter of
urgency using material from randomized studies of in-
traperitoneal chemotherapy to demonstrate whether par-
ticular molecular subgroups have more to gain from
intraperitoneal treatment. It is already clear that some
molecular subgroups have a high incidence of primary
platinum resistance (Fig. 3; homologous recombination
proficient),55,56 and these patients may not benefit from
intraperitoneal therapy; instead, perhaps they should be
considered for dose-dense paclitaxel and carboplatin ad-
ministered intravenously, or trials of other novel therapies
in combination with their first-line chemotherapy, to op-
timize survival and avoid unnecessary toxicity.
Although “cure” is a word that most ovarian cancer on-
cologists try to avoid, this must be our aim. The survival that
has been demonstrated in patients with completely
cytoreduced disease and who received intraperitoneal
chemotherapy in the GOG172 study is a sea change in terms
of what we expect in this disease. It reinforces the argument
that in fit patients, maximal cytoreductive surgery followed
by intraperitoneal chemotherapy is the treatment likely to
produce the best possible outcome. However, the morbidity
induced by both these treatments makes it even more im-
perative that we are able to define whether it is only patients
with a particular biology (e.g., BRCA mutations or homolo-
gous recombination deficiency) that benefit. For these pa-
tients, “full-on” surgical/intraperitoneal chemotherapy with
or without PARP maintenance inhibitors (depending on the
outcome of currently running first-line PARP inhibitor
studies) could be adopted. For the patients with different
biology, alternative tailored approaches could be sought.
CONCLUSION
Large randomized phase III studies have been ubiquitously
positive, producing some of the best survival data ever seen
in the treatment of ovarian cancer. However, all of these
studies have had issues, either with the intravenous che-
motherapy (control) arm being perceived as no longer con-
temporary or the intraperitoneal (test) arm having higher
dose intensity than the control arm and, therefore, not
being a trial solely of route of administration. These apparent
shortcomings combined with undoubted toxicity of the ap-
proach have led to inconsistent uptake in North America and
Australia and negligible uptake in Europe. This seems a shame
given that the benefits in terms of outcome appear so
marked. Indeed, the benefits are well in excess of those
demonstrated in the first-line bevacizumab studies that led to
licensing and reimbursement of this agent across Europe.
Further work is required to improve the toxicity from
chemotherapy administered intraperitoneally and to iden-
tify the best regimen and determine the extent to which the
benefits witnessed also can be produced by dose-dense
approaches or the use of targeted agents. These latter
two questions may be answered to some extent by the
GOG252 study. Perhaps the most important question that
requires to be answered is exactly which molecular sub-
groups of ovarian cancer patients benefit most from
FIGURE 3. Molecular Subgroups of High-Grade Serous
Epithelial Ovarian Cancer
Abbreviations: HRD, homologous recombination deficient.
asco.org/edbook | 2016 ASCO EDUCATIONAL BOOK 149
INTRAPERITONEAL CHEMOTHERAPY IN THE TREATMENT OF OVARIAN CANCER
intraperitoneal treatment. If this can be established, these
patients may benefit greatly from an aggressive surgical and
intraperitoneal chemotherapy approach. The question is,
will this be enough to change practice?
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